Home » Topics » Science » New compound

New compound
RSS

SG-3-00802 shows encouraging preclinical activity in combination with anti-PD-1 therapy

Oct. 8, 2021

Preclinical assessment of the novel GLP-1 receptor agonist GZR-18

Oct. 6, 2021

JSF-3151 demonstrates efficacy in mouse model of MRSA infection

Oct. 5, 2021

GlaxoSmithKline details discovery of new class of BET BD2 inhibitors

Oct. 4, 2021

ER-001259851-000, novel selective Axl inhibitor with promising PK profile in vivo

Sep. 30, 2021

GSK-852 identified as a soluble BET inhibitor selective for BD2

Sep. 30, 2021

Potent inhibitor of sAC shows potential as nonhormonal contraceptive

Sep. 27, 2021

Preclinical evaluation of novel mAChR subtype-selective M1 PAMs

Sep. 23, 2021

VU-6028418 reverses cataleptic behavior in rat models

Sep. 17, 2021

SCN-16 targets the Keap1-Nrf2 protective pathway to treat ALI

Sep. 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...